CD274 and colorectal carcinoma: Beneficial effects in patients with advanced CRC have been achieved using ICIs due to the activation of the immune response, particularly by blocking the combination of activated T cells and PD‐L1, which otherwise compromises the immunity in patients with CRC.33, 34